Warnex Will Use LC/MS and PCR Tools in PGx Study of Gleevec for Novartis | GenomeWeb
NEW YORK (GenomeWeb News) — Warnex today said Novartis has hired it to perform bioanalytical and pharmacogenetic services for the drug maker’s leukemia and intestinal tumors program.

Warnex said its Bioanalytical Services division will use its liquid chromatography and mass spec technologies to test blood levels of Novartis’ drug Gleevec to “help identify non-adherence or suboptimal dosing.”

Warnex also will perform PCR-based diagnostic tests to determine if patients have chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.